Novartis on course to set new highs

20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."

Executive summary
Conflict of interest

Pages

Language

English

Published on

20/02/24

Download

You may also be interested by these reports :

17/11/25

Ipsen

Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...

14/11/25

H Lundbeck

The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...

13/11/25

Merck

The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...

12/11/25

Bayer

The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue